Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

Article Abstract:

Human monoclonal antibodies (mAbs) are expressed in the small aquatic plant Lemna minor, which has offered many advantages for manufacturing therapeutic proteins free of zoonotic pathogens. The resultant mAbs has contained a single major N-glycan species without detectable plant-specific N-glycans and had better antibody-dependent cell-mediated cytotoxicity and effector cell receptor binding activities than mAbs expressed in cultured Chinese hamster ovary (CHO) cells.

United States, Lemnaceae

---

Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting

Article Abstract:

The fusion of two complementarity-determining regions (CDRs), [V.sub.H]CDR1 and [V.sub.L]CDR3, through a cognate framework region ([V.sub.H]FR2) has produced mimetics that have retained the antigen recognition of their parent molecules, but have a superior capacity to penetrate tumors. The rational recombination of selected [V.sub.H]/[V.sub.L] binding sites and their framework regions have provided useful moieties for cytotoxic cancer therapies.

Tumors, Tumours, Immunoglobulin allotypes

---

Monoclonal antibody therapy of cancer

Article Abstract:

An overview of mAb therapy of cancer, emphasizing few advances that have clarified the utility of mAbs to treat common malignancies such as breast cancer, colorectal cancer and lymphoma, is provided. These successes have energized and informed the development of many new antibodies that target previously tested and new targets for cancer therapy.

Similar abstracts:

• Abstracts: Estimation of hand force in ergonomic job evaluations. Quo vadis, neuroergonomics? Providing cognitive support with technology-based warning systems
• Abstracts: Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Rapid generation of specific antibodies by enhanced homologous recombination
• Abstracts: Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Stem cell-derived erythroid cells mediate long-term systemic protein delivery
• Abstracts: Human antibodies from transgenic animals. Generation of cloned transgenic pigs rich in omega-3 fatty acids. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
• Abstracts: Complementary therapies for inflammation. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.